Rami Manochakian/X
Jun 30, 2025, 14:51
Rami Manochakian: MARIPOSA Trial and Latest Developments in the Treatment of EGFR+ NSCLC
Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared a post on X about a paper he co-authored with colleagues published in ASCO Daily News:
“Hot off the press.
Just published on ASCO Daily News.
Editorial Article by our team, Mayo Clinic Comprehensive Cancer Center on:
MARIPOSA trial and latest developments in the Treatment of EGFR+ non-small cell lung cancer (NSCLC).
Very proud of outstanding 1st author/mentee, chief fellow Reema Tawfiq, and excited to co-author first article with my amazing friend/colleague and new chair Vamsi Velcheti.”
Title: The Butterfly Effect: Rethinking First-Line Therapy in Advanced EGFR-Mutant NSCLC After MARIPOSA
Authors: Reema Tawfiq, Rami Manochakian, Vamsi Velcheti
You can read the Full Article in ASCO Daily News.
More posts featuring Rami Manochakian.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 19, 2025, 02:39
Jul 18, 2025, 21:36
Jul 18, 2025, 21:35
Jul 18, 2025, 19:26
Jul 18, 2025, 19:23
Jul 18, 2025, 18:53